ReviewJournal of clinical medicine2021
Landscape of Preterm Birth Therapeutics and a Path Forward.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Nestorone, a potent progestin, exhibits anti-inflammatory activity and prevents preterm birth in murine models of premature labor.American journal of obstetrics and gynecology · 2026Article
- Dual-Targeted Nanotherapy Restores Redox Homeostasis and Suppresses Uterine Hypercontractility for Effective Preterm Birth Intervention.Advanced healthcare materials · 2026Article
- ASC-Derived Extracellular Vesicles Suppress Macrophage-Driven Inflammatory Amplification and Contractile Activation of Uterine Smooth Muscle Cells.International journal of molecular sciences · 2026Article
- An update on pacemaking in the myometrium.The Journal of physiology · 2026Review
- Novel liquid-based approaches for transmucosal drug delivery.Acta pharmaceutica Sinica. B · 2026Review
- Tocolytic agents and the failure to improve neonatal outcomes.Pregnancy (Hoboken, N.J.) · 2026Article
- Phenotypes of Preterm Birth: A Retrospective Cohort Study from a Tertiary Romanian Centre as a Framework for Future Genomic and Proteomic Research.Journal of clinical medicine · 2026Article
- Targeting SAA expression via siRNA mitigates preterm birth induced by maternal inflammation.Frontiers in pharmacology · 2026Article
- A novel modulator of IL-6R prevents inflammation-induced preterm birth and improves newborn outcome.EMBO molecular medicine · 2025Article
- Human Cervix Chip: A Preclinical Model for Studying the Role of the Cervical Mucosa and Microbiome in Female Reproductive Health.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025Review
- Article
- The drug drought in maternal health: an ongoing predicament.The Lancet. Global health · 2024Review
- Phenanthroline relaxes uterine contractions induced by diverse contractile agents by decreasing cytosolic calcium concentration.European journal of pharmacology · 2024Article
- Addressing a broken drug pipeline for preterm birth: why early preterm birth is an orphan disease.American journal of obstetrics and gynecology · 2023Article
- Metabolomic profiling of preterm birth in pregnant women living with HIV.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- Article
- Vaginal Nanoformulations for the Management of Preterm Birth.Pharmaceutics · 2022Review
- Diagnostic or Therapeutic Strategies for Pregnancy Complications.Journal of clinical medicine · 2022Article
- Social Isolation Stress Modulates Pregnancy Outcomes and the Inflammatory Profile of Rat Uterus.International journal of molecular sciences · 2022Article
- The contribution of racism-related stress and adversity to disparities in birth outcomes: evidence and research recommendations.F&S reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 3 countries.
Funding
Abstract
Preterm birth (PTB) remains the leading cause of infant morbidity and mortality. Despite 50 years of research, therapeutic options are limited and many lack clear efficacy. Tocolytic agents are drugs that briefly delay PTB, typically to allow antenatal corticosteroid administration for accelerating fetal lung maturity or to transfer patients to high-level care facilities. Globally, there is an unmet need for better tocolytic agents, particularly in low- and middle-income countries. Although most tocolytics, such as betamimetics and indomethacin, suppress downstream mediators of the parturition pathway, newer therapeutics are being designed to selectively target inflammatory checkpoints with the goal of providing broader and more effective tocolysis. However, the relatively small market for new PTB therapeutics and formidable regulatory hurdles have led to minimal pharmaceutical interest and a stagnant drug pipeline. In this review, we present the current landscape of PTB therapeutics, assessing the history of drug development, mechanisms of action, adverse effects, and the updated literature on drug efficacy. We also review the regulatory hurdles and other obstacles impairing novel tocolytic development. Ultimately, we present possible steps to expedite drug development and meet the growing need for effective preterm birth therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.